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Abstract
In advanced HIV infection, the homeostatic balance between gastrointestinal indigenous bacteria and gut immunity fails
and microbes are able to overcome the intestinal barrier and gain the systemic circulation. Because microbial translocation
is not fully controlled by antiviral therapy and is associated with inefficient CD4+ reconstitution, we investigated the profile
of translocating bacteria in peripheral blood of 44 HIV-infected patients starting therapy with advanced CD4+ T-
lymphopenia and displaying poor CD4+ recovery on virologically suppressive HAART. According to CD4+ reconstitution at
12-months HAART, patients were considered Partial Immunological Responders, PIRs (CD4+$250/ml, n=29) and
Immunological non Responders, INRs (CD4+,200/ml, n=15)). We show that PIRs and INRs present similarly elevated
plasma levels of lipopolysaccharide (LPS) and its ligand sCD14 that were not lowered by virologically suppressive therapy.
Bacterial 16S rRNA gene amplification and sequencing resulted in a highly polymicrobic peripheral blood microbiota both
prior and after 12-month HAART. Several differences in bacterial composition were shown between patients’ groups, mainly
the lack of probiotic Lactobacillaceae both prior and after therapy in INRs. Failure to control microbial translocation on
HAART is associated with a polymicrobic flora circulating in peripheral blood that is not substantially modified by therapy.
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Introduction
HIV infection causes dramatic damage to the gastrointestinal
(GI) tract, that includes substantial disruption of gut microbiota
composition with presence of microbes at higher pathogenic
potential compared to less aggressive indigenous organisms,
massive loss of gut-residing CD4+ T-cells, and down-regulation
of GI tract genes expression [1,2,3].
Thus, a substantial breach of the anatomo-functional GI barrier
occurs, with progressive failure of mucosal immunity and leakage
into the systemic circulation of bacterial by-products, such as
lipopolysaccharide (LPS) and bacterial DNA fragments, which
contribute to systemic immune activation [1] [4,5,6].
Highly active antiretroviral therapy (HAART) only partially
amends GI tract antomo-functional damage [1,7] and intestinal
microbiota, further hampering intestinal homeostasis [8] and
sustaining microbial translocation [9,10]. Thus, although circulating
microbial products have been shown to decrease during HAART,
they remain elevated, in turn affecting immune restoration [1,4,7].
In untreated HIV/AIDS, the highest degree of microbial
translocation has been shown in patients with severe immune
depression [1,4]. Similarly, following HAART initiation, patients
with blunted long-term CD4+ recovery show persistently elevated
circulating LPS and bacterial DNA independently of HIV viremia
reduction [1,4,11]. Moreover, elevated microbial translocation as
well as failure to contain it in the course of virologically-
suppressive HAART have been associated to an increased risk
of HIV disease progression and death [7,12].
Given the relationship between microbial translocation and
CD4+ reconstitution, we asked whether HIV-infected patients
with ongoing microbial translocation despite virologically effective
HAART, maintain a polymicrobic flora translocating in periph-
eral blood possibly with an imbalanced ratio of harmless
indigenous organisms to pathogenic species. Should this supposi-
tion be verified, the next question to be addressed would be
whether systemic microbiota may affect immune reconstitution.
Thus, we aimed to investigate the composition of translocating
microflora in peripheral blood of HIV-infected patients with poor
CD4+ T-cell recovery on virologically-suppressive HAART. We
specifically chose to focus on a group of HIV-infected patients
starting therapy with severe immune depletion of #200 CD4+/ml,
because the extent of CD4+ T-lymphopenia is inversely related to
microbial translocation [1,11], and is a major determinant of
immune reconstitution on HAART [13,14,15].
Results
Patient characteristics
We prospectively studied 44 HIV-infected antiretroviral-naive
patients starting HAART with severe CD4+ depletion (#200
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63 (28–117)/ml. At 12 months of HAART, patients’ median (IQR)
CD4+ T-cell count was 281 (180–357)/ml.
At 12 months HAART, 29 (67%) were Partial Immunological
Responders (PIRs, HIV-RNA,60 copies/mL; CD4+$250/ml),
and 15 (33%) were Immunological non Responders (INRs, HIV-
RNA,60 copies/mL; CD4+,200/ml). Patients’ demographics
and clinical features at baseline and month 12 are shown in
Table 1.
HIV+ patients starting HAART with severe CD4+
T-lymphopenia display persistently elevated microbial
translocation
As expected, when compared to HIV-negative controls, HIV+
patients as a whole displayed significantly higher T0 and T12
sCD14 (HIV2 1,96 (1,9–2,3) mg/mL; HIV+, T0 3,07 (2,7–4,1)
mg/mL, HIV+, T12 4,26 (2,8–8,5) mg/mL, p=.0001), confirming
enhanced microbial translocation.
PIRs and INRs displayed comparable baseline circulating LPS:
PIRs, 75 (52–82) pg/mL; INRs, 75 (51–85) pg/mL; p=.95, and
sCD14: PIRs: 3,18 (2,7–4,5) mg/mL; INR: 3,07 (2,8–3,9) mg/mL;
p=.73) (Table 1). Interestingly, by 12 months of HAART, no
major changes in LPS and sCD14 levels were shown in both PIRs
and INRs (LPS, T12: PIRs, 75 (62–139) pg/mL; INRs, 75 (65–
114) pg/mL; p=.2 and p=.36 for T0 vs T12 in PIRs and INRs,
respectively; sCD14, T12: PIRs, 4,26 (2,5–8,5) mg/mL; INRs, 3,85
(2,8–11,6) mg/mL; p=.1; p=.5 for T0 vs T12 in PIRs and INRs,
respectively) (Table 1).
INRs present increased circulating 16S rDNA levels
Because the finding of equally elevated circulating LPS despite
divergent CD4+ recovery on virologically-suppressive HAART
was somehow unexpected, we set out to further characterise
microbial translocation by investigating bacterial DNA composi-
tion in plasma.
At baseline, 14/44 (32%) HIV+ patients yielded a positive 16S
rRNA gene PCR amplification, with a significantly higher
proportion of PCR-positive INRs (INRs: 8/15, 53%; PIRs: 6/
29, 20%; p=.04). At T12, 7/44 (16%) HIV+ patients were PCR-
positive, with a non significantly higher proportion of INRs: INRs:
4/15 (27%); PIRs: 3/29 (10%); p=.21. No PCR amplification was
yielded in HIV-negative controls.
HIV+ patients starting HAART with severe CD4+
T-lymphopenia display a polymicrobic circulating
bacterial microbiota
Following amplification, 10 representative bacterial colonies/
patient were sequenced. Thus: at T0, 8 PCR+ INRs made up to
80 sequenced bacterial colonies, and 6 PCR+ PIRs corresponded
to 60 sequenced bacterial colonies; at T12, 4 PCR+ INRs made up
to 40 sequenced bacterial colonies, and 3 PCR+ PIRs corre-
sponded to 30 sequenced bacterial colonies.
Sequencing analysis of HIV positive patients as a whole
revealed multiple bacterial orders for each patient with no
differences in the bacterial composition between baseline and
T12 (Figure 1). In particular, between T0 and T12, we found a
similar proportion of patients displaying bacteria belonging to
Enterobacteriales (T0: 13/14, 93%; T12: 7/7, 100% p=.75),
Lactobacillales (T0: 8/14, 57%; T12: 5/7, 71% p=1), Pseudomona-
dales (T0: 6/14, 43%; T12: 4/7, 57% p=1), Burkholderiales (T0: 8/
14, 57%; T12: 3/7, 43% p=.74) and Bacillales (T0: 3/14, 21%;
T12: 2/7, 29% p=1).
However, when we divided HIV+ patients in PIRs and INRs we
found differences in bacterial composition between the two groups
at baseline and T12 (Figure 2–4).
In terms of bacterial order, we found a similar baseline
proportion of PIRs and INRs displaying bacteria belonging to
Enterobacteriales (PIRs: 5/6, 83% vs INRs: 8/8, 100%, p=.43),
Lactobacillales (PIRs: 4/6, 67% vs INRs: 4/8, 50%; p=.63),
Burkholderiales (PIRs: 2/6, 17% vs INRs: 6/8, 75%; p=.28) and
Bacillales (PIRs: 2/6, 17% vs INRs: 1/8, 12%; p=.54) (Figure 2A
and B). A significantly higher proportion of PIRs displayed
Table 1. Patients’ characteristics.
CHARACTERISTICS FRs (n=29)
INRs
(n= 15)
HIV-
(n=13) p
Age, years (IQR) 40 (32–48) 36 (29–52) 27 (25–32) .002
Sex, Male 21 13 2 .001
Risk Factors
Eterosex 15 9 N/A
Omosex 7 2
IDU 3 1
Time since 1st
HIV-Ab+, years
(IQR)
4 (2–6) 6 (1–7) N/A
Duration HAART,
months (IQR)
30 (15–59) 28 (12–64) N/A
HCV-Ab (yes) 32N / A
Previous AIDS
diagnosis (yes)
14 9 N/A
CD4+ T Cells (cells/mL)
(n) (IQR)
N/A
Nadir 70
a,b (40–140) 35
b (13–56)
12 months after HAART 330
a
(281–399)
166
(127–189)
Plasma HIV-1 RNA
Log(cp/mL) (IQR)
N/A
Zenith 5,17
b
(4,81–5,69)
4,78
b
(4,16–5,16)
12 months after HAART 1,7
(1,70–1,78)
1,7
(1,70–1,78)
Antiretroviral therapy,
number
N/A
NRTI+PI 28 15
NRTI+NNRTI 1 0
Microbial T
ranslocation Markers
sCD14 (mg/mL) (IQR)
Baseline 3,18 (2,7–4,5 3,07 (2,8–3,9) 1,96
(1,39–2,4)
.002
12 months after HAART 4,26
(2,5–8,5)
3,85
(2,8–11,6)
.001
LPS(pg/mL) (IQR)
Baseline 75 (52–82 75 (51–85) 75
(75–79,41)
.567
12 months after HAART 75 (62–81) 75 (65–114) .947
NOTE: Data are median (IQR -Interquartile range-). FRs: Full Responders; INRs :
Immunological Non Responders; IDU: intravenous drug user; HAART: highly
active antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor;
NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
ap,.01 for FRs vs INRs;
bp,.01 for T0 vs T12.
doi:10.1371/journal.pone.0018580.t001
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p=.026) (Figure 2A and B).
No major changes in bacteria composition were shown
following 12 months of HAART in both patients’ groups
(Figure 2A and B).
After identifying bacterial orders, we set out to investigate
bacterial families (Figure 3A and B) and genera (Figure 4A and B).
At baseline, a significantly higher proportion of PIRs displayed
Lactobacillaceae (3/6, 50% vs 0/8 0%; p=.05) and Pseudomonadaceae
(5/6, 83% vs 1/8, 13%; p=.026) as compared to INRs (Figure 3A
and B). In particular, the differences concerned Lactobacillus sp
(PIRs 3/6, 50% vs INRs 0/8 0%; p=.05) and Pseudomonas sp 5/6,
83% vs 1/8, 13%; p=.026) (Figure 4A and C).
After 12 of months HAART in both patients’ groups, no
significant changes were shown in bacteria families (Figure 3A and
B) and genera (Figure 4B and D).
Discussion
Through the joint quantification of gut-derived bacterial
macromolecules and genotypes, we hereby assessed the quality
of microbial translocation in peripheral blood of HIV-infected
patients starting HAART with severe immune depression and
lacking CD4+ recovery on therapy, and have made the following
observations. First, severely immune depressed HIV-infected
patients fail to efficiently control translocation of microbial
macromolecules following HAART initiation. Second, HIV-
infected patients maintaining heightened microbial translocation
on virologically-suppressive HAART display a circulating micro-
biota that is polymicrobic at the genotype level and that is not
substantially modified by therapy.
Both LPS/sCD14 plasma levels have been described to
decrease following HAART initiation [1,4,11,16]. However, while
patients starting HAART with high CD4+ counts present a
substantial LPS/sCD14 plasma reduction that is inversely
correlated with the magnitude of CD4+ recovery [1,4], a less
efficient containment of microbial translocation has been shown in
naı ¨ve patients starting therapy with low CD4+ [11,16]. Accord-
ingly, we hereby describe that patients with severe CD4+ T-
lymphopenia at HAART initiation maintain heightened circulat-
ing LPS/sCD14 after 12 months of therapy despite HIV-viremia
control.
A possible explanation of the less efficient control over microbial
translocation in this patients’ cohort might be consistent with the
dramatic structural damage of the intestinal barrier described in
untreated advanced HIV/SIV infection [9,17], with ever-increas-
ing content of microbial by-products infiltrating intestinal lamina
propria and gaining the circulation. The GI tract damage and
occurring microbial translocation might be hardly repaired by the
late institution of therapy, in turn favouring the continuous
passage into the systemic circulation of a highly polymicrobic
intestinal flora. Furthermore, in these patients a delayed decrease
in sCD14/LPS plasma levels following HAART initiation.
Increased levels of circulating microbial by-products and
markers of immune response to microbial translocation have been
associated to increased HIV disease progression and mortality
even in the context of continuous antiviral therapy and
independently of CD4+ count and HIV-viremia [7,12], advocat-
Figure 1. Characterization of translocating microflora in HIV+ antiretroviral naive patients. Patients’ plasma samples were examined
before and after 12 months of HAART for the presence and identification of DNA bacterial fragments using a broad-range 16S rRNA gene PCR
amplification followed by sequencing analysis. At baseline, 14/44 (32%) HIV+ patients yielded a positive PCR amplification, whereas at T12, 7/44 (16%)
HIV+ patients were PCR-positive. Sequencing analysis of HIV positive patients as a whole revealed multiple bacterial orders for each patient with no
differences in the bacterial composition between baseline and T12. Positive (%)=# patients displaying a specific bacterial order/total # of PCR
positive patients. Negative (%)=# patients negative for a specific bacterial order/total # of PCR positive patients.
doi:10.1371/journal.pone.0018580.g001
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or risk of clinical progression on HAART. However, by showing
that following 12 months of virologically-suppressive HAART,
HIV-infected patients with advanced immune depression fail to
control microbial translocation and microbial-driven monocyte
activation and maintain elevated free LPS/sCD14, our findings
seem to suggest that the quantification of LPS/sCD14 may not be
sufficient to predict immunological failure to HAART in these
patients. Research directly comparing sCD14/LPS levels changes
on HAART in patients with different CD4+ counts at HAART
start as well as longer patients’ follow-up are needed to further
confirm such hypothesis.
The main finding of our research is that HIV-infected patients
starting therapy with severe CD4+ depletion display a circulating
microbiota that is highly polymicrobic at the genotype level and
that is not substantially modified by therapy.
Figure 2. Characterization of translocating microflora in PIRs and INRs. Bacterial microflora translocating in peripheral blood was evaluated
in 44 HAART-naive patients with severe immune depression (CD4+#200/mL) at baseline and after 12 months of stable HAART (T12). At T12, 29
patients were partial immunological responders -PIRs- (CD4+$250/mL; VL,60 cp/mL) and 15 were immunological-non-responders -INRs-
(CD4+,200/mL; VL,60 cp/mL). At baseline, we found a significantly higher proportion of PCR-positive INRs (INRs: 8/15, 53%; PIRs: 6/29, 20%;
p=.04). At T12 a non significantly higher proportion of INRs yielded a positive 16S gene PCR amplification: INRs: 4/15 (27%); PIRs: 3/29 (10%); p=.21.
PIRs and INRs displaying a similar bacterial orders both at baseline and T12, except Pseudomonadales order *(FRs 5/6, 83% vs 1/8, 12% p=.026).
Positive (%)=# patients displaying a specific bacterial order/total # of PCR positive PIRs (or INRs). Negative (%)=# patients negative for a specific
bacterial order/total # of PCR positive PIRs (or INRs).
doi:10.1371/journal.pone.0018580.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18580Figure 3. Identification of bacterial families in PIRs and INRs. Positive (%)=# patients displaying a specific bacterial family/total # of PCR
positive PIRs (or INRs). Negative (%)=# patients negative for a specific bacterial family/total # of PCR positive PIRs (or INRs). PIRs and INRs presented
a different profile in term of bacteria families. (A) PIRs displayed a similar composition of bacterial families between baseline and T12. (B) No major
changes in bacterial families were seen in INRs after 12 months-HAART. At baseline, the significant differences between the two groups concerned
Blood Microbiota and Immunity
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a bacterial population enriched with Enterobacteriales, whereas less
than 60% display the probiotic Lactobacilllales, with the same
proportion being maintained on virologically-suppressive
HAART.
Interestingly, despite equal circulating LPS, we observed some
differences in the composition of translocating microflora in
patients with different extent of CD4+ T-cell recovery on
virologically suppressive HAART.
In particular, in INRs we describe the presence of the more
potentially pathogenic Enterobacteriaceae with no evidence of
Lactobacillus spp.. Lactobacillus spp. possess immunomodulatory and
anti-inflammatory properties [18], including suppression of pro-
inflammatory cytokines production from E.coli LPS-activated
monocytes [19]. This might result in disproportionate antigenic
challenge that is not contained by counter-regulatory bacterial-
derived factors, overall exacerbating immune activation.
Despite our study was not designed to identify statistically
significant associations between peripheral blood microbial
genotypes and immunological outcome, these findings highlight
the potential correlations between the bacterial species in the
systemic circulation and immune reconstitution. Thus, our
research should be used to generate hypotheses to be tested in
larger studies aimed at investigating the role of translocating
bacteria in the regulation of mucosal and systemic immune
homeostasis, and the association with HAART-driven immune
reconstitution.
From a mechanistic standpoint, our research detail a poly-
microbic translocating flora including pathogenic and symbiotic
bacteria in severely immune-depressed HIV+ patients, which is
not seen in HIV-negative subjects, and is not reverted by
virologically-suppressive therapy, suggesting substantial failure of
gut immunity in controlling bacteria translocation [1,2]. Several
concurring mechanisms likely contribute to such polymicrobic
Figure 4. Bacterial genera identified in plasma sample of PIRs and INRs. Positive (%)=# patients displaying a specific bacterial genera/total
# of PCR positive PIRs (or INRs). Negative (%)=# patients negative for a specific bacterial genera/total # of PCR positive PIRs (or INRs). (A–B)A
similar composition of bacterial genera were seen in PIRs both at T0 and T12. (C–D) INRs presented no variation in bacterial genera following 12
months of HAART. At baseline, significant differences between PIRs and INRs were seen for Lactobacillus sp *(PIRs 3/6, 50% vs INRs 0/8 0%; p=.05)
and Pseudomonas sp *(PIRs 5/6, 83% vs INRs 1/8, 13%; p=.026). No differences between the two groups at T12.
doi:10.1371/journal.pone.0018580.g004
Lactobacillaceae *(PIRs 3/6, 50% vs INRs 0/8 0%; p=.05) and Pseudomonadaceae *(PIRs 5/6, 83% vs INRs 1/8, 13%; p=.026). No differences between
PIRs and INRs at T12.
doi:10.1371/journal.pone.0018580.g003
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macrophage dysfunctions, persistent gut epithelia barrier damage
or loss of GI tract Th17 cells [6,20,21].
Our study has several limitations. The PCR, cloning and
sequencing techniques that we used are somehow outdated and
have been replaced by more modern techniques such as
pyrosequencing [22][23]. Potential biases of our experimental
approach include more efficient amplification of certain bacteria
versus others, and low sensitivity of the assay.
A further limitation is the number of colonies analysed per
patient. Increasing the number of colonies sequenced per patient
as well as the number of patients studied overall would certainly
give a deepest/adequate representation of the microbiota present
in peripheral blood of HIV-infected patients.
However, the identification of statistically relevant associations
between peripheral blood microbial genotypes and immune
recovery was beyond the purpose of our study. Indeed, the main
finding of our research is that HIV-infected patients starting
therapy with severe CD4+ depletion display a circulating
microbiota that is highly polymicrobic at the genotype level and
that is not substantially modified by therapy: these findings are
already evident by sequencing 10 colonies/patient.
Although the conclusions of our study are based on a limited
number of patients and thus very preliminary, this is to our
knowledge the first report to suggest polymicrobial translocation of
gut flora in HIV-infection. Further research is needed in patients
with different CD4+ counts at HAART start as well as longer
patients’ follow-up to further confirm such hypotheses.
This might also provide a rational basis for the investigation of
adjuvant therapeutical approaches aimed at recovering the
symbiotic host-microorganism relationships, in turn containing
chronic systemic inflammation and contributing to a more efficient
immune reconstitution on HAART [24].
Methods
Patients
We longitudinally investigated 44 HIV-infected antiretroviral-
naive patients, starting HAART with severe CD4+ depletion of
#200 cells/mL. After 12 months of stable HAART, we divided
HIV-infected individuals into two groups according to viro-
immunological response to therapy: (i) Partial Immunological
Responders -PIRs, HIV-RNA,60 copies/mL and CD4+ count
$250/ml in at least three consecutive determinations; (ii)
Immunological non Responders -INRs, HIV-RNA,60 copies/
mL and CD4+ count ,200/ml in at least three consecutive
determinations. Exclusion criteria were initiation of therapy
during primary HIV infection, signs or symptoms of gastrointes-
tinal disease and chirrosis.
As controls, we studied plasma samples from 13 HIV-negative
healthy subjects.
All enrolled patients provided written informed consent
according to the Ethical Committee of our Institution (Comitato
Etico, Ospedale ‘‘San Paolo’’ and Comitato Etico, Milan, Italy).
The ethics committee (Comitato Etico, Ospedale ‘‘San Paolo’’
and Comitato Etico, Milan, Italy) specifically approved this
study.
Plasma LPS and sCD14
Microbial translocation was evaluated by plasma levels of
lipopolysaccharide (LPS) (LAL test; Kinetic-QCL; Bio Whittaker,
Walkersville, MD, USA) and sCD14 (ELISA assay, R&D, Italy),
according to manufacturer’s protocols.
Broad-range PCR for measurement of bacterial 16S rRNA
gene
Bacterial DNA detection was performed using a broad-range
16S rRNA gene PCR amplification followed by sequencing
analysis in all 44 HIV+ patients and 13 HIV2 controls. Following
DNA extraction, PCR amplification was performed as previously
described [25], with the following thermal cycler conditions: 94uC
for 5 min, 40 times for 1 minute each time at 94uC, 55uC and
72uC, and 10 min at 72uC. To confirm DNA integrity, we also
amplified the housekeeping gene beta-globin. Standard PCR
precautions were taken to avoid samples cross-contaminations.
Cloning and Sequencing of PCR products
The 360-bp PCR products were cloned into the pCRH2.1 -
TOPOH Vector (Invitrogen, San Diego, California, USA.) and 10
representative bacterial colonies per patient were sequenced
(ABIHPRISM 3130XL Genetic Analyzer, Applied Biosystem,
Foster City, CA, USA). Only 98–100% homologies by ‘‘Basic
Local Alignment Search Tool’’ (BLAST) were considered valid.
Statistical analysis
All continuousvariableswerepresentedasmedian 6 interquartile
ranges (25
th–75
th percentile), while categorical data were shown as
absolute numbers and percentages. Quantitative values were tested
for normality with Shapiro-Wilk test and all the analyzed variables
deviated from normality. Pearson’s chi square or Fisher’s exact tests
were used to evaluate associations of the categorical variables
between HIV2 healthy subjects and HIV+ patients or among
HIV2 healthy subjects, PIRs and INRs. The Mann Whitney U test
with the Montecarlo method for small samples was used for the
comparison of continuous parameters between the 2 groups, while
eventual differences among the three groups of patients were
explored with Kruskal-Wallis test. Results of bacterial sequencing
analysis are presented as # of patients displaying a specific bacterial
order, family, species/total # of PCR-positive patients. To compare
the percentages of PCR positive-negative between INRs and PIRs
and between different timepoints (T0 and T12) inthe same groupof
patients, we used Pearson’s chi square or Fisher’s exact tests. The
same statistic test was used to analyze eventual differences in
bacterial composition (orders, families and species) between PIRs
and INRs and between T0 and T12. A value of p,0.05 was
considered denoting statistical significance. Statisticswereperformed
using SPSS software (version 17.01; SPSS).
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